BRPI0818437A8 - anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma - Google Patents

anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma

Info

Publication number
BRPI0818437A8
BRPI0818437A8 BRPI0818437A BRPI0818437A BRPI0818437A8 BR PI0818437 A8 BRPI0818437 A8 BR PI0818437A8 BR PI0818437 A BRPI0818437 A BR PI0818437A BR PI0818437 A BRPI0818437 A BR PI0818437A BR PI0818437 A8 BRPI0818437 A8 BR PI0818437A8
Authority
BR
Brazil
Prior art keywords
antibody
pharmaceutical composition
hybridoma
antibodies
bone metabolism
Prior art date
Application number
BRPI0818437A
Other languages
English (en)
Inventor
Tsuda Eisuke
Hiruma Yoshiharu
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40549216&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0818437(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BRPI0818437A2 publication Critical patent/BRPI0818437A2/pt
Publication of BRPI0818437A8 publication Critical patent/BRPI0818437A8/pt
Publication of BRPI0818437B1 publication Critical patent/BRPI0818437B1/pt
Publication of BRPI0818437B8 publication Critical patent/BRPI0818437B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)

Abstract

anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma. fornecer um método de detectar metabolismo ósseo anormal usando um gene fortemente expresso em um osteoclasto; um método de triar um composto tendo um efeito terapêutico e/ou preventivo para metabolismo ósseo anormal; e uma composição farmacêutica para tratar e/ou prevenir metabolismo ósseo anormal. fornecimento de um método de detectar metabolismo ósseo anormal usando a expressão de gene de siglec-15 humano como um índice; uma composição farmacêutica contendo um anticorpo que reconhece especificamente siglec-15 humano e tem uma atividade de inibir formação de osteoclastos; e os semelhantes.
BRPI0818437A 2007-10-11 2008-10-08 anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma BRPI0818437B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007265420 2007-10-11
JP2007-265420 2007-10-11
PCT/JP2008/068287 WO2009048072A1 (ja) 2007-10-11 2008-10-08 破骨細胞関連蛋白質Ｓｉｇｌｅｃ－１５を標的とした抗体

Publications (4)

Publication Number Publication Date
BRPI0818437A2 BRPI0818437A2 (pt) 2015-05-12
BRPI0818437A8 true BRPI0818437A8 (pt) 2019-01-15
BRPI0818437B1 BRPI0818437B1 (pt) 2021-03-30
BRPI0818437B8 BRPI0818437B8 (pt) 2021-05-25

Family

ID=40549216

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0818437A BRPI0818437B8 (pt) 2007-10-11 2008-10-08 anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma

Country Status (25)

Country Link
US (5) US8546540B2 (pt)
EP (2) EP2206727B1 (pt)
JP (4) JPWO2009048072A1 (pt)
KR (2) KR101534884B1 (pt)
CN (2) CN108130327A (pt)
AU (2) AU2008311698C1 (pt)
BR (1) BRPI0818437B8 (pt)
CA (2) CA2875310A1 (pt)
CY (1) CY1116432T1 (pt)
DK (1) DK2206727T3 (pt)
ES (2) ES2677246T3 (pt)
HK (2) HK1145847A1 (pt)
HR (1) HRP20150485T1 (pt)
HU (1) HUE025262T2 (pt)
IL (2) IL204607A (pt)
MX (1) MX2010003884A (pt)
NZ (1) NZ583397A (pt)
PL (1) PL2206727T3 (pt)
PT (1) PT2206727E (pt)
RU (2) RU2475499C2 (pt)
SG (2) SG187523A1 (pt)
SI (1) SI2206727T1 (pt)
TW (1) TWI511740B (pt)
WO (1) WO2009048072A1 (pt)
ZA (1) ZA201001339B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI359026B (en) 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
US8168181B2 (en) * 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
WO2007093042A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
SI2206727T1 (sl) 2007-10-11 2015-06-30 Daiichi Sankyo Company, Limited Protitelo, ki cilja osteoklast - soroden protein Siglec-15
NZ605450A (en) * 2009-04-09 2014-07-25 Daiichi Sankyo Co Ltd Anti-siglec-15 antibody
MX2013003828A (es) * 2010-10-05 2013-06-28 Daiichi Sankyo Co Ltd Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos.
JPWO2012050154A1 (ja) * 2010-10-13 2014-02-24 学校法人東京女子医科大学 抗ｖｄａｃ抗体を含有する破骨細胞形成抑制剤
JP6216317B2 (ja) * 2011-09-09 2017-10-18 メディミューン リミテッド 抗Ｓｉｇｌｅｃ−１５抗体およびその使用
WO2013147212A1 (ja) * 2012-03-30 2013-10-03 第一三共株式会社 新規抗Ｓｉｇｌｅｃ－１５抗体
EP2832857B1 (en) 2012-03-30 2018-01-03 Daiichi Sankyo Company, Limited Cdr-modified anti-siglec-15 antibody
US9493562B2 (en) 2012-07-19 2016-11-15 Alethia Biotherapeutics Inc. Anti-Siglec-15 antibodies
US9951123B2 (en) 2013-09-30 2018-04-24 Daiichi Sankyo Company, Limited Anti-LPS O11 antibody
US10479832B2 (en) 2014-03-31 2019-11-19 Universiteit Gent Method of treating bone disease
AU2016286898B2 (en) 2015-06-29 2022-12-08 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
DK3515478T3 (da) 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
SG10201912368XA (en) 2017-02-07 2020-02-27 Daiichi Sankyo Co Ltd Anti-gprc5d antibody and molecule comprising the antibody
TWI782000B (zh) 2017-03-30 2022-11-01 日商第一三共股份有限公司 抗ｇｐｒ２０抗體、其製造方法及其應用
EP3646885A4 (en) 2017-06-30 2021-04-28 National University Corporation Hokkaido University MEDICINAL PRODUCTS AGAINST OSTEOPOROSIS IN CHILDREN WITHOUT CAUSING GROWTH DISORDERS
CA3071234A1 (en) 2017-07-27 2019-01-31 Daiichi Sankyo Company, Limited Anti-cd147 antibody
WO2019230869A1 (ja) 2018-05-31 2019-12-05 第一三共株式会社 抗ヒトｔｌｒ７抗体
WO2020022475A1 (ja) 2018-07-27 2020-01-30 第一三共株式会社 抗体－薬物コンジュゲートの薬物部位を認識する蛋白質
CN111378043B (zh) * 2020-02-19 2021-02-09 南京医科大学 一种具有中和作用的人鼠嵌合抗Siglec-15全分子IgG及其制备方法和应用
CN112159475B (zh) * 2020-10-10 2021-04-30 南京凯地生物科技有限公司 Siglec-15单克隆抗体及其应用
CN112625132B (zh) * 2021-01-15 2022-08-02 沈阳荣欣生物制药科技有限公司 纳米抗体及其编码基因、表达载体、宿主细胞和应用
CN114957468A (zh) * 2021-02-25 2022-08-30 石药集团巨石生物制药有限公司 一种抗Siglec15抗体及其用途
CN112979761B (zh) * 2021-03-19 2021-12-10 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN112961214B (zh) * 2021-03-19 2022-08-02 江苏元本生物科技有限公司 一种靶向Siglec-15的噬菌体多肽
CN113577283A (zh) * 2021-07-19 2021-11-02 河北医科大学第三医院 Siglec-15抑制剂在制备防治骨巨细胞瘤药物中的应用
CN114807052A (zh) * 2022-06-07 2022-07-29 江苏亲科生物研究中心有限公司 Siglec15单克隆抗体及其制备方法和用途
WO2024022008A1 (zh) * 2022-07-26 2024-02-01 北京东方百泰生物科技股份有限公司 一种抗Siglec-15单克隆抗体、其抗原结合片段及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
PT1696031E (pt) 1991-12-02 2010-06-25 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
DE69333823T2 (de) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn Verfahren zur herstellung von gliedern von spezifischen bindungspaaren
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
IL117175A (en) 1995-02-20 2005-11-20 Sankyo Co Osteoclastogenesis inhibitory factor protein
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
KR100496063B1 (ko) 1997-04-15 2005-06-21 산쿄 가부시키가이샤 신규단백질 및 그 제조방법
AU752031B2 (en) 1998-05-08 2002-09-05 Toyama Chemical Co. Ltd. Novel spiro compounds or salts thereof, agent for preventing and/or treating autoimmune diseases and AP-1 inhibitors containing the same
IL153542A0 (en) * 2000-07-21 2003-07-06 Bristol Myers Squibb Co SIALIC ACID BINDING Ig-RELATED LECTIN PROTEINS
US7608704B2 (en) * 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
CA2428140A1 (en) 2000-11-08 2002-05-16 Incyte Genomics, Inc. Secreted proteins
WO2002064771A1 (fr) * 2001-02-15 2002-08-22 Mochida Pharmaceutical Co., Ltd. Nouvelle molecule d'adhesion cellulaire specifique de leucocyte active
CN1547486A (zh) * 2001-06-26 2004-11-17 抗opgl抗体
AU2002364699A1 (en) 2001-11-13 2003-06-17 Incyte Genomics, Inc. Receptors and membrane-associated proteins
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
EP1494714A4 (en) 2002-04-05 2008-03-05 Amgen Inc HUMAN ANTI-OPGL NEUTRALIZING ANTIBODIES AS SELECTIVE OPGL PATH HEMMER
PT1583830E (pt) 2003-01-07 2006-11-30 Symphogen As Método para produzir proteínas policlonais recombinantes
JP4633491B2 (ja) * 2004-02-12 2011-02-16 第一三共株式会社 破骨細胞関連タンパク質を標的とした抗体
TWI359026B (en) * 2004-02-12 2012-03-01 Sankyo Co Pharmaceutical composition for the osteoclast rela
US7405037B2 (en) 2004-05-07 2008-07-29 Lonza Walkersville, Inc. Methods and tools for detecting collagen degradation
CN101035807A (zh) * 2004-06-09 2007-09-12 泰勒公司 Siglec－6相关疾病的诊断和治疗
JP4604184B2 (ja) * 2005-07-12 2010-12-22 独立行政法人産業技術総合研究所 新規糖鎖認識蛋白質及びその遺伝子
GB0521991D0 (en) * 2005-10-28 2005-12-07 Univ Dundee Siglec-9 binding agents
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
WO2007093042A1 (en) 2006-02-13 2007-08-23 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
SI2206727T1 (sl) * 2007-10-11 2015-06-30 Daiichi Sankyo Company, Limited Protitelo, ki cilja osteoklast - soroden protein Siglec-15
NZ605450A (en) 2009-04-09 2014-07-25 Daiichi Sankyo Co Ltd Anti-siglec-15 antibody
CA2803489C (en) 2010-06-23 2017-08-01 Creissels Technologies Installation with overhead cables and vehicles served thereby, without hanger
MX2013003828A (es) 2010-10-05 2013-06-28 Daiichi Sankyo Co Ltd Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos.
EP2832857B1 (en) 2012-03-30 2018-01-03 Daiichi Sankyo Company, Limited Cdr-modified anti-siglec-15 antibody
WO2013147212A1 (ja) 2012-03-30 2013-10-03 第一三共株式会社 新規抗Ｓｉｇｌｅｃ－１５抗体

Also Published As

Publication number Publication date
AU2008311698A1 (en) 2009-04-16
KR101577935B1 (ko) 2015-12-16
JP5845207B2 (ja) 2016-01-20
TWI511740B (zh) 2015-12-11
US10723800B2 (en) 2020-07-28
US9815899B2 (en) 2017-11-14
WO2009048072A1 (ja) 2009-04-16
EP2907826B1 (en) 2018-05-30
AU2012201263A1 (en) 2012-03-22
HK1145847A1 (en) 2011-05-06
US20180037656A1 (en) 2018-02-08
AU2012201263B2 (en) 2017-04-20
CN108130327A (zh) 2018-06-08
CY1116432T1 (el) 2017-02-08
JP6116652B2 (ja) 2017-04-19
EP2206727A1 (en) 2010-07-14
KR20150031489A (ko) 2015-03-24
RU2010106639A (ru) 2011-08-27
CA2698326A1 (en) 2009-04-16
AU2008311698B2 (en) 2011-12-01
ES2677246T3 (es) 2018-07-31
IL234078A0 (en) 2014-09-30
EP2206727B1 (en) 2015-04-01
US10308715B2 (en) 2019-06-04
US20150344578A1 (en) 2015-12-03
RU2475499C2 (ru) 2013-02-20
BRPI0818437B1 (pt) 2021-03-30
ZA201001339B (en) 2010-10-27
IL204607A0 (en) 2010-11-30
NZ583397A (en) 2012-03-30
US20120230988A1 (en) 2012-09-13
DK2206727T3 (en) 2015-07-06
RU2012132678A (ru) 2014-02-10
TW200927168A (en) 2009-07-01
HUE025262T2 (en) 2016-02-29
AU2008311698C1 (en) 2014-03-06
AU2012201263B9 (en) 2017-06-01
EP2206727A4 (en) 2011-03-02
BRPI0818437B8 (pt) 2021-05-25
EP2907826A1 (en) 2015-08-19
SI2206727T1 (sl) 2015-06-30
US20120251485A1 (en) 2012-10-04
CN101896501A (zh) 2010-11-24
JP2016074694A (ja) 2016-05-12
KR101534884B1 (ko) 2015-07-08
US20100209428A1 (en) 2010-08-19
CN101896501B (zh) 2017-11-07
JP2017155044A (ja) 2017-09-07
US9090692B2 (en) 2015-07-28
PL2206727T3 (pl) 2015-08-31
US8546540B2 (en) 2013-10-01
CA2698326C (en) 2015-03-17
JPWO2009048072A1 (ja) 2011-02-17
ES2540733T3 (es) 2015-07-13
HRP20150485T1 (en) 2015-06-19
JP2013144708A (ja) 2013-07-25
BRPI0818437A2 (pt) 2015-05-12
SG187523A1 (en) 2013-02-28
KR20100065153A (ko) 2010-06-15
CA2875310A1 (en) 2009-04-16
PT2206727E (pt) 2015-08-05
MX2010003884A (es) 2010-04-30
IL204607A (en) 2016-03-31
IL234078B (en) 2018-08-30
JP6440759B2 (ja) 2018-12-19
SG10201605897RA (en) 2016-09-29
HK1209135A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
BRPI0818437A8 (pt) anticorpo ou fragmento funcional do anticorpo, composição farmacêutica, uso de pelo menos um dos anticorpos ou fragmentos funcionais dos anticorpos, e, hibridoma
BRPI0507645A (pt) anticorpo, método de detectar um distúrbio ósseo metabólico, kit para detectar um distúrbio ósseo metabólico, composição farmacêutica para o tratamento de um distúrbio ósseo metabólico, e, método de triar uma substáncia efetiva para tratar e/ou prevenir um distúrbio ósseo metabólico
BRPI1009381A2 (pt) compostos, composição farmacêutica, método para tratar doença ou condição associada com função de trap1 em sujeito em necessidade do mesmo e uso de compostos e composição farmacêutica
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
CL2007000478A1 (es) Anticuerpo humano o humanizado o fragmento funcional del mismo especifico para linfopoyetina estromal timica, tslp; polinucleotido que lo codifica; celula huesped que lo comprende; composicion farmaceutica que comprende al anticuerpo; y metodo para t
BRPI0907135B8 (pt) uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica
MX349513B (es) Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
CO6390109A2 (es) Inhibidores de syk de imidazopirazina
BRPI0813311A2 (pt) Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica.
BR112012008665A2 (pt) tratamento de câncer
BR112013028779B8 (pt) proteína de ligação de antígeno ou imunoconjugado, imunoconjugado, composição farmacêutica, e, uso de uma composição
BRPI0511139B8 (pt) compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BRPI0622054B8 (pt) composto e composição farmacêutica
BRPI0715975A2 (pt) Fragmento imunogênico de pcpa, composição,recipiente, métodos de gerar anticorpos específicos para pcpa em um indivíduo, de prevenir ou reduzir portador nasal pneumocócico em um indivíduo, e de reduzir o risco de uma infecção pneumocócica em um indivíduo, e, polipeptídeo isolado
BR112012020101A2 (pt) método diagnósticos e terapêuticos usando anticorpos anti-cd200.
BRPI0618577A8 (pt) Usos de rituximab
BR112012001984B8 (pt) anticorpos humanos com alta afinidade para angiopoietina-2 humana, uso dos mesmos e composição farmacêutica
BR112013006395A2 (pt) moduladores do receptor de estrogênio e seus usos.
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
BR112016008010A2 (pt) uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose
BR112015007144A2 (pt) uso de masitinib para o tratamento de câncer em subpopulações de paciente identificadas usando fatores prognosticadores
BRPI0816097A2 (pt) composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: A CLASSIFICACAO ANTERIOR ERA: F04B 39/00

Ipc: C07K 16/28 (1995.01), C07K 14/42 (1995.01), A61K 3

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF